KRED

Tuesday, June 13, 2017

WeissLaw LLP: The Proposed Acquisition of SciClone Pharmaceuticals Inc. May Not Be In the Best Interest of SCLN Shareholders

http://ift.tt/1b8drIa

NEW YORK, June 12, 2017 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of SciClone Pharmaceuticals Inc. (“SCLN” or the “Company”) (NASDAQ: SCLN) in connection with the proposed acquisition of…

June 13, 2017 at 03:10AM

http://ift.tt/2roBBWo

from

http://ift.tt/2roBBWo